DCC-2812 / Ono Pharmaceutical, Deciphera Pharmaceuticals - LARVOL DELTA

An open-label phase 1 study of DCC-2812 monotherapy in patients with advanced genitourinary cancers. (ASCO 2026) - P1 | "Secondary outcome measures include radiographic objective response rate and radiographic duration of response per Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Working Group 3 criteria, if applicable, as well as pharmacokinetics. The study is currently recruiting patients at multiple sites in the United States."

Clinical • Metastases • Monotherapy • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Deciphera Pharmaceuticals, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Deciphera Pharmaceuticals, LLC

Monotherapy • New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer